Abstract: FR-PO159
Identification of Hub Biomarkers and Inflammation-Related Pathways Participating in the Progression of AKI
Session Information
- AKI: Mechanisms - II
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 103 AKI: Mechanisms
Authors
- Chen, Qiuju, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
- Zhang, Xiao, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
- Xu, Zhenjian, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
- Xu, Anping, Sun Yat-Sen Memorial Hospital, Guangzhou, Guangdong, China
Background
Acute kidney injury (AKI) is a common, potentially devastating condition associated with markedly increased morbidity and mortality. We aim to identify key biomarkers involved in the progression of AKI and search for potential therapeutic target.
Methods
Microarray datasets GSE87025 and GSE192532 were integrated and batch effect was removed through ComBat. Hub markers for AKI were mined based on differential expression analysis, weighted gene co-expression network analysis (WGCNA) and lasso regression, followed by GO and KEGG term analysis. The results were further validated in GSE81741 and GSE153625.
Results
A total of 474 differential genes were screened. Eight co-expression modules were obtained via WGCNA; of which, blue module had the highest correlation with AKI. A total of 270 intersecting genes were acquired by combining differential genes. Six hub markers (Serpina3n, Rrad, Lgals3, Il1rn, Slc34a2, Micall2) were subsequently obtained by lasso analysis as potential biomarkers for AKI. ROC curve analysis demonstrated a prime diagnostic value of the six hub markers. According to the functional enrichment analysis of the differential genes, hub markers were mainly elevated in inflammation-related pathways.
Conclusion
Six hub markers were identified which might be involved in the progression of AKI via inflammation-related signal pathways. Further studies are needed to validate our findings and explore effective strategies for AKI targeting these hub genes.
Fig 1. Identification of Hub Genes
Fig 2. Validation of hub genes in the diagnostic value.
Funding
- Government Support – Non-U.S.